Humanigen has publicized a poster on Lenzilumab - making neurotoxicity from CAR-T less likely as well as making CAR-T more effective - https://www.mdedge.com/hematology-oncology/article/195018/transplantation/anti-gm-csf-antibody-reduced-car-t-cell-toxicity -All tge writing is on the wall for a GILD buyout - though we’ll probably do better without it in the end.